Agenus Inc Overview
Industry: Biotechnology
Sector: Healthcare
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGF TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and displa Read MoreReported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $34.5M (reported).
Revenue
$34.5M
reported
What changed
- Revenue reported to $34.5M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
Aug 07, 2026
SEC filing
8-K
Aug 06, 2026
SEC filing
10-Q
May 11, 2026
SEC filing
8-K
May 11, 2026
Earnings release
Earnings release
May 11, 2026
SEC filing
10-K
Mar 16, 2026
SEC filing
8-K
Mar 16, 2026
Earnings release
Earnings release
Mar 16, 2026
SEC filing
10-Q
Nov 10, 2025
SEC filing
8-K
Nov 10, 2025
Earnings release
Earnings release
Nov 10, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Agenus earnings missed by $0.02, revenue was in line with estimates
Headline from Investing.com Nigeria: Agenus earnings missed by $0.02, revenue was in line with estimates.
Agenus: Q2 Earnings Snapshot
Headline from Yahoo Finance: Agenus: Q2 Earnings Snapshot.
Agenus earnings missed by $0.02, revenue was in line with estimates
Headline from Investing.com UK: Agenus earnings missed by $0.02, revenue was in line with estimates.
Agenus earnings missed by $0.02, revenue was in line with estimates
Headline from Investing.com: Agenus earnings missed by $0.02, revenue was in line with estimates.
Agenus (AGEN) Stock Fair Value Falls After Analysts Rework Pipeline And Financing Assumptions
Headline from Yahoo Finance: Agenus (AGEN) Stock Fair Value Falls After Analysts Rework Pipeline And Financing Assumptions.
AGEN 8-K & SEC Filings
Headline from Yahoo Finance: AGEN 8-K & SEC Filings.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.